Strong uptake puts pressure on Lenacapavir stocks
South Africa’s twice-yearly HIV-prevention injection has drawn strong interest, but limited supplies and high costs threaten to slow its expansion beyond the first six provinces.
South Africa’s twice-yearly HIV-prevention injection has drawn strong interest, but limited supplies and high costs threaten to slow its expansion beyond the first six provinces.